Emerging viruses like SARS-CoV-2 and Ebola necessitate rapid antiviral drug development. Strategies include targeting viral replication (e.g., protease inhibitors) and host immune responses. Remdesivir and molnupiravir, developed for COVID-19, exemplify broad-spectrum antivirals.
Challenges include viral mutations and lengthy clinical trials. High-throughput screening and AI-driven drug design accelerate discovery. Future efforts focus on pan-viral therapies effective against multiple virus families.
SREENU THALLA , et al. "Antiviral Drug Development for Emerging Viruses".
OpenJournal system, VOL 1, Issue 1, Case Study.DOI: https://doi.org/9q3292475342987544